Good morning, ladies and gentlemen. Welcome to the YDUQS video conference to discuss the results referring to the Q3 2026. This video conference is being recorded, and the replay can be accessed on the company's website, www.yduqs.com.br. The presentation is available for download also on the company's website. Please be advised that all participants will only be watching the video conference during the presentation, and then we will start the Q&A session when further instructions will be provided. Before proceeding, we would like to clarify that any statements that may be made during this video conference regarding the company's business prospects, projections, and operational and financial goals are beliefs and assumptions of YDUQS' board of directors based on the current information available to the company. Those statements may involve risks and uncertainties as they relate to future events and therefore depend on circumstances that may or may not occur.
Investors, analysts, and journalists should take into account that events related to the macroeconomic environment, the education segment, and other factors that could cause results to differ materially from those expressed in the respective forward-looking statements. For a better view of the presentation, we recommend enabling full-screen mode. Present at this video conference, we have Mr. Rossano Marques, CEO of YDUQS, and Mr. Alexandre Aquino, CFO. I'd like to turn the floor over to Mr. Rossano Marques, who will begin the presentation. You may proceed, Mr. Marques.
Good morning, everyone. Thanks for being here of Q3 2026. We have another very strong performance. Alexandre is here to share good news with you. Starting with highlights of the quarter, strong cash generation that we had in the company, historic record of BRL 364 million generated in this quarter, 23% compared to previous year.
When we look at the nine months, 2026 to 2025, very high cash generation as we commented. This gives us reassurance with the guidance early this year. We had between BRL 520 million-BRL 620 million. We generated in the past nine months of 2026, BRL 565 million, reassuring the rest of the year. Very confident in the delivery of our net income per share or earnings per share. This leads us to the path that we have designed in the past. Strong leverage reduction from YDUQS Day. We said that the priority of capital allocation would be in reducing leverage. This path will follow with potential approval of the merger that we have to have it approved by our general meeting and by CADE.
We formed the basis of this business and a combined company with strong dividend distribution that we'll have between signing and closing the combined company would get to 1.2x leverage. Reducing leverage is very important in terms of capital allocation. This is actually a result of the three main verticals I'm going to start talking about, Estácio, YDUQS, and delivering a number that makes us feel very proud. On-campus undergrad, it has relevant growth. We're seeing this happening. We know on-campus suffered a lot with the end of FIES during the pandemic as well, and we started identifying the past semesters a trend of stabilization of this number.
We told the market that we viewed in the short term the curve turning and on-campus resuming a growth curve, and this was above what we expected, and this showed that we were following a successful path in all the on-campus teaching sites. We have very well-prepared campuses for this new stage. We streamlined our structure, prepared it for a new market reality. Now it is ready to grow with profitability in a very opportune moment. We see the growth now, and we see the first signs of intake. It is early to talk, but added to the positive result of the second half, we see initial results based on the number of enrollments that we have first semester 2027, makes us feel excited, and we are still recovering ticket. This has been something we told the market.
We saw space for recovering ticket on-campus, also growing 8% year-over-year in YDUQS and Estácio space. We have a semi-undergrad intake. We started behind in our main. Considering our main competitors, we had different strategies. We have been doing that in the past two years, and we have very positive results when we exclude that raise. In the first quarter of 2025, we compare semi-undergrad and nursing, we see very strong growth. Even without including nursing, we see very strong growth. The quarter has been very positive for Estácio and YDUQS overall. For Ibmec, we still have a growth of intake. We see more details, and what is nice is that we are opening 2027 a new campus in Fortaleza. We have a very high volume of enrollments above what we planned.
It makes us feel very confident that it will be very successful, very positive signs showing ascertained national expansion strategy. It is going to grow for yet a few years with the implementation of the Fortaleza campus growing and undergrad student base overall. We are very confident with Ibmec, IDOMED. IDOMED has an intake that is very high. We started with a cloud, large number of courses. We knew we would have more competitiveness in the market. We started with certain intake restrictions because of ENAMED last year. Even with those restrictions, we had a record number of intake, over 3,000 students intake. Very strong number for IDOMED, even with the restrictions we had. The ROL keeps growing in undergraduate. Another number that impresses, considering greater competition in the market, is renewal rate at 97%, much higher for IDOMED.
Moving to this overview of revenue EBITDA. We had 2% growth.
Few factors impacted it, quite similar to what we saw previously. We had some specific items that led to a slight drop in EBITDA of a higher margin. This should be due to the impact we had in expenses, causes a slight distortion, does not impact our general view. We show here briefly the continuity of the evolution of penetration in IDOMED and Ibmec, our premium blocks, and our EBITDA as a whole. We mentioned that the company, if the merger with Afya will go to 2/3 of EBITDA coming from the premium segment after the merger.
Moving at IDOMED, as we said, the highlight here is the volume of 3,000 students intake. We have 100 seats approved, so we have 2,500 seats approved, so we have 3,000 students reached with the external transfer shows our attractiveness and initial move of intake.
A lot of students are transferred, reaching this record volume of 3,000 students in 2026. We had certain penalties caused to the ENAMED results in 2025. Even so, we saw a strong volume, very much based on our intake strategy over the year and the power of the brand that attracts students over the course. We see the revenue growth of 7% year-over-year, more or less the same student base, even with the ticket reduction caused to high penetration of FIES. The only negative impact of this higher FIES penetration is that there is a ticket reduction due to the size of FIES. The students stay longer, and the permanence level improves profitability of FIES, but has a negative impact on revenue. It grows in line with the student base.
We have exceeded inflation to all upperclassmen, keeping tickets stable, and they are referenced in all marketplaces, always operating based on our guidance. This excess of competition in the Brazilian market brought by seats could actually impact it, but the quality of the IDOMED product and the strength of our brand keeps our levels high. As to margins, IDOMED is one of those generators, has a specific negative impact on the margin on the Q3 due to the investments we made, the improvement of our academic body, and we feel that ENAMED was held a while ago. We made some investments to ensure that we could have good results. We are very optimistic with the results that should come out in December, should improve financial results as of 2027 with the drop in certain dropouts.
We had, IDOMED had the drop, this negative result in Q3 part due to displacement of revenue or expenses and more spending that we had in Q3 due to the quality and also geared specifically to the ENAMED test. We had very good appropriateness of our students. We wanted to improve and ensure good performance for the examination, ENAMED, and this had an impact in the margin in the Q3, and we had a difference in the Q4. We had to drop 1.5 percentage point, and we should recover that in Q4, going back to a level to 1 percentage point, then 1.5%. This 50% margin should be target margin for the next years of IDOMED, more or less the level we are working with. As to Ibmec, is a great. We have Fortaleza, a new market we are going to start in 2027. Initial numbers are fantastic.
We have a volume of enrollments well above what we expect, shows the ascertained strategy of starting operations in Fortaleza. With all the signs that we have, they are very positive, they ensure very strong intake. Moving into a market we never operated before. This happens bringing yet another course that will have five years for maturation. We maturing in Brasília and Faria Lima. We have growth contract in those two markets. And for now, this we have brings yet five more years of growth and maturation. This happens as we increase intake ticket. It is growing more than 5% in all markets. It shows the strength of the brand. We can keep on growing in intake and attracting more students of better quality.
We see renewal above 96%, showing the quality of teaching and the students that we have, and the strength of the brand, not only in intake, but also retention. To the specific thing, most of displacement that we have of revenue from the third to Q4 impacted with elections. That is something that impacts those specific moments of availability. We have B2B, B2C, but our outlook is very positive. We know that our share in postgrad is much lower than undergrad, and we have full certainty that we are going to recover the share. A lot of graduate studies of EMAG, which was quite similar to undergraduate, another growth, a great lever of growth in the forthcoming quarters. On the Estácio & Wyden slide, we feel very happy to see the numbers of on-campus intake that we were betting on it. We saw that previously.
On-campus suffered a lot after FIES, the pandemic. We had to restructure the business and shrinking our footage, our number of associates to adapt to our new reality. We worked to adapt all our structure that we read to had. Adapting everything on our campuses, improving NPS of students, working on those moments that we viewed as were going to happen, and it has been happening. The volume had been stabilizing at levels that were quite stable, and we saw the recovery this quarter. We see recovery close to the slow single digits. This quarter is above what we expected. Intake growth of 8%, followed by numbers I have mentioned previously of intake first semester 2027 that has been doing quite well. Numbers are still initial. It is the very beginning.
If we see a lot of enrolled students doing quite well, and we can have positive results on-campus indicating a curve above. We talked above in the beginning, and that was being impacted by the World Cup, expectation of elections. We saw things speeding up after the World Cup, bringing very positive result. At the end of election, those initial numbers that are very strong, giving us a visibility that in 2027, that was expected previously. In addition to on-campus, we saw the growth of semi, and the highlights we had on the courses, excluding nursing, the growth was close to 20%. But it is impressive how the semi on-campus is a strong lever for us. Although we started late, we learned fast. We learned from the lessons of those that came before, and semi on-campus has been a very valuable product in this strategy.
We are very well positioned for this new regulatory framework. We incorporated half of what the cost would be in 2026, and the other half will come in 2027. We had an impact that we expected, 0.7% impact on the margin. This happened partially in 2026, and we will have the rest in 2027. But clearly, we have very well-prepared structure to absorb this migration that has been happening, very fast growth in semi on-campus. We have a lot of students on our campuses and our hubs, and we expand our semi on-campus hubs. When we look at ticket, as we have been talking, on-campus keeps growing 8% in terms of revenue, brings a lever of sustainability of this long-term growth. While for digital, kind of stable, semi on-campus, well, it is a more aggressive move to attract those students, as we believe this should stabilize as of next year.
Looking a bit at the margin is kind of stable year-over-year, 2025 against 2026, the specific margin of the Q3. You have a slight drop, basically motivated due to displacement. I think we'll have some comments on that, but we make a yearly sale of the performed portfolio. Last year, we had the sale on the third quarter. This has not happened in Q3. It should happen in Q4 to show this slight displacement of margin. It does not impact the margin year-over-year. That should be stable with a potential improvement for Q4. Our costs and expenses. The first highlight is relevant drop in non-recurring. Number that was not well received by the market.
We said that it was due to punctual or specific items [ at Perfect] where we started, where we've been telling the market that our second semester, we had much lower levels, and we had this reduction that was important in Q3. We'll have another major reduction in Q4. Looking at Q3, we see that the discipline and cost and expense have been strong in our company, removing this negative variation of bad debt. Then we compare the nine months with the three months of Q3, we see we had a reduction over the year of almost 1 percentage point, a bit over 1 percentage point in bad debt year-over-year. This is more stable.
They're basically due to the change in the quarter when we sell the portfolio of delinquent students that has been written off, that last year had a positive impact of BRL 15 million in our results, a bit over that. So this quarter, we would have a bad debt 1% below last year. This is a relevant change. Another move we had here was in marketing and sales. We had a World Cup elections period that increased costs slightly to our expenses there. After elections, we realized that we had the opportunity of speeding up our intake, and we made a few more investments where we have a growth of 1.2 percentage points compared to Q3 last year. But over the year, this growth is about 0.4%. We see a Q4 where we go back to a level similar to what we've had over the year.
Looking at net income, we had relevant growth when we adjust less the or lower addition to DIS . There's a short-term impact that is negative to revenue a bit. It has positive impact to cash generation in the midterm. It actually reduces the bad debt. To make a fair comparison, we have the impact of DIS that is very short term. Looking at the other lines that we have EBITDA, as it was impacted by DIS, the financial results, we had negative impact due to the interest rates, a leak. So it will be reverted in Q4. It will be 1.25 percentage points. It was 15% last year, now it is 13.75%. Additionally, we have a positive effect of depreciation amortization.
We mentioned that with the drop that we had that was progressive of our level of investment in the recent years, depreciation amortization takes a bit longer to be combined or to reach this level that is lower in terms of recent investment. We have about BRL 50 million between our depreciation and our current investment level. Part of this difference is being reduced this year, and we will see a new reduction in Q4. The last item of variation that is negative, we had in the part of taxes, lower recognition of deferred items, that is accounting issue, no impact to the cash. At the bone in accumulated last 12 months, we have BRL 1.43 earnings per share within the guidance we gave to the year. It should be proven in Q3 because we have several positive things compared to Q4 last year.
At the end, we will talk about those levers, right?
Yes.
In terms of cash generation, I think this is the great highlight of the quarter. As we know, we have done several things. The impact of our moves in terms of revenue, EBITDA, a negative generate positive impact to cash generation. That is the case of provision for engaged students. In Q3, we had the highest cash generation, not only for Q3, for any quarter of the company of all times, 23% higher than last year. With this generation, we reach half of the guidance that we gave for the year, BRL 520 million-BRL 620 million of cash generation for shareholders in 2026. Q4 tends to be a cash generator that is close to zero due to very recurring effect that we have in Q4, and this will be different this year. This helped us the cash generation of this quarter.
Receivables, we moved from 88 days last year to 72 this year, days of sales outstanding, significant reduction. This is due to the work of many hands from the non-engaged program, drop of DIS, more renewal of our students, leading our bad debt to drop. At some point, we see many actions here with the payment terms, and it performs and actually leads to lower bad debt. So we have 70 days of sales outstanding, should be very good. So this is sustainable improvement. Actually, we still have improvements to happen next year, right? So we follow this trajectory that is sustaining for many years. So we still have a lot of work in the forthcoming years.
Very good.
Let's move on to debt. Only good news. We have had very interesting trajectory here of reducing our debt spread. We started at 2% in 2023.
After a new organization of the 13th debenture in the third quarter of 2026, we got to 0.9 percentage points. We are paying CDI + 0.9%. The other relevant point here is that we extended our debt, moving from 2.9x medium term to 3.5x, and we had an issuance. So we had an exchange in the market. We had 66% approximately of the 10th debenture, changing debt that would mature 2028, 2029 to 2031, 2032, and 2033. So extended it, reducing the spread. So we had an issuance of BRL 450 million for cash resources, taking a good moment in the market, and we have certain reductions that in the head. So cash positioning that is very comfortable. We managed with this cash generation that was record in Q3.
We were able to speed up the deleveraging of the company, which is a commitment we have with our shareholders until we reach the end of next year at one time.
Speaking of financial results, let's see what the process of the merge with Afya. You know that on the 23rd of September , we signed the agreement. Last week, we called upon the Extraordinary General Meeting. This will happen on the 25th of November . So this will be the general meeting, and then we have 12 months after signing, we expect to have the final approval CADE and actually do everything that is required between signing and closing.
We set up an integration office to work in the team, the integration management office, with the two teams dedicated executives working exclusively on this project, isolated from our operations, working on those six folders, academic architecture, talent, culture and change, organization compensation, IT architecture, so that we can get to the closing to start in the fastest and smoothest way, capturing all the value that we have been generating. Obviously, we're very focused on the operation, but we have the team taking care of this merger that we strongly believe in terms of its value generation for our business. So we have our traditional ESG slide, makes us feel very proud, and that's part of our DNA. We have our award for the third consecutive year, the ESG Integrity Yearbook , to see our students and professors working with the community.
Several fronts, so we have legal, law school providing services, the health schools or medical schools providing services to the communities where we operate. And the third highlight is employability, that is core for YDUQS. It's key for the success of a higher education institution, provide employability to our students. So we have over 876,000 students engagements of students supported by YDUQS, specific vacancies, and setting up several partnerships to strengthen our possibility of employability, coordinated by AWS, NFL. So I'm a fan of American football, and this is an opportunity for our students that is great. To conclude, we're very confident on our guidance of earnings per share on net revenue. Would you like to talk about it?
Sure. So we have speeding up revenue of the year.
So this quarter, we had the revenue with the growth close to zero, and then we started having closer or higher growth in Q3. When we talk about bad debt, we had phasing of a sale of portfolio that happened in Q3. Now it's going to happen in Q4. We're going to have significant reduction in Q4 year-over-year. And financial result last is impacting positively due to the drop in the interest rate. We had 15%, last year it's 13.75%. This generates a relevant impact in addition to the drop of our leverage to the financial results we're going to expect to have in Q4.
We've reached the end of our presentation. Let's highlight cash generation. That is a very important number to us following the strong profile of the company, strong cash generator.
We promise payment of dividends between signing and closing to generate over 32% of our shareholders, or 32% of dividend yield through closing without tackling the leverage we have in the company. So the combined company in the future should have 1.2 x net debt. EBITDA should be a great dividend payment, and the cash generation will support several initiatives of cash allocation for both companies. We follow consistently in terms of operations. They were very straight, which shows the performance of on-campus this quarter. We have adapting operations post-FIES, post-pandemic, adapting the organization according to what we believe will happen. Now we are reaping the benefits. We have 8% intake on-campus, and the ticket there reinstates our thesis of Estácio & Wyden, showing the rigorous discipline of the company, and also paving the way for 2027. We are looking forward to what we are going to have.
We have a specific team working on the planning of this team. We had hired this top-notch consulting firm to plan on the synergies, to work on the plans, and now the team is working along with the consulting firm to fine-tune everything that will be done so that we have great synergy. We are very confident that we will capture all synergies with very smooth transition. We are very concerned with the cultural process of integration. We do this very carefully, and yet we are very confident that the synergies will be captured, possibly faster than we have on the plan, and we are working to fine-tune all these things to everything to reaffirm the guidance of earnings per share and also net income for the year. So we close the presentation, we move on to Q&A, and I would like to thank you all for your participation.
I will be happy to answer your questions, both myself, Aquino, and all the team. Thank you very much.
We will now start the Q&A session for investors and analysts. If you wish to ask a question, please press the reaction button and then click on raise hand. If your question is answered, you can also leave the queue by clicking on lower your hand. Our first question comes from Samuel Alves from BTG Pactual.
Good morning, everyone. Two questions. The first on EBITDA margin you mentioned during the presentation, just to understand the drop on Q4, if you had a cost/expense displacement that led to that and ended up to being a bit higher. If you could explore this. The fourth, you are talking about smaller amount of one-off. What do you expect amount of one-off in Q4, considering the merger with Afya?
Should you have some amount of non-recurring related to this corporate movement in Q4? If you could talk about this a bit. Thank you.
Good morning, Samuel. Thank you for your questions. On the first EBITDA margin, the main factors linked to this displacement of revenue, smaller revenue of graduate of lifelong second semester, or second semester actually, due to elections, and we have government as important source for Vida Toda or lifelong. I know we follow in its natural flow, so we have this placement of revenue in graduate and a drop, a slight drop in undergraduate. This is a certain part of this drop in margin is recovered in Q4. We do not see relevant displacements of revenue follow positive trajectory for EBITDA margin, both in closing 2026 and also the 2027 outlook. Second question, great, important topic to talk about non-recurring. It is a topic that was warmer last year.
Over the years, we had a sequence of non-recurring expenses focused on restructuring the on-campus business, suffered a lot in the volume post-FIES after pandemic. We had to adjust on-campus structures, both physical and personnel. The spending occurred for this to happen. Q3 last year, we had expenses to reduce corporate structure. After the restructuring we went through, that was important cycle until 2025. We said then 2026, the volume would be greatly reduced, clearly visible in second semester 2026. This is happening. You see non-recurring dropping a lot in second half of 2026. This is consistent. We will continue in the next quarters. The idea is to move away from this non-recurring expenses to reduce structure.
This is concluding, and that is why we are going to have specific events as it is the merger with Afya should generate some non-recurring expense in Q4, not sufficient to not to generate this drop.
That is very important in non-recurring. These things strengthen the view of our positive cash flow. When we compare adjusted EBITDA with cash, we sudden have non-recurring expenses. This overall of non-recurring will actually benefit this cash view that I talk about [inaudible ]. I hope I have addressed your point. Thanks for your question.
Thank you. Good day.
Our next question is from Vitória Antonello from JP Morgan.
Good morning. Thanks for taking my questions. Two on my side. You mentioned a bit about intake of 2027.1, that you are optimistic with what you see. Could you comment a bit further on what you see in every specific segment? On-campus, semi, digital? What about the demand? Second question is on the 6x1 scale. Do you see any impact? How are you working on this in the company if there is an impact?
How do you plan to mitigate those costs, the weekly scale 6x1 being banned?
Thank you for your question, Vitória. First, 2027.1 intake, very positive outlook. Very early, we see a trend that is being carried from 2026.3 positive to 2027.1. Important with this market that is relevant, so in this cycle of intake, we only become more optimistic. Seems to be a trend that has been carried since post-World Cup. This is important in Q3 intake, especially on-campus. We started July with the same difficulty of Q1, coinciding with the World Cup. When the period was over, we got back to being more present in the media. We spend a bit more, the sales and marketing costs higher. So this happened, actually as of August, it seems to be continuing. End of Q3, early fourth quarter, we have intake of 2026.
We turn our attention for intake in 2027.1. You generate revenue in 2027. We see the number of enrolled students with quite relevant growth compared to previous year. And in the beginning of the cycle of financial enrollments is quite significant year-over-year. In your question in the segment, this is very strong in on-campus and semi on-campus. We had strong growth in semi on-campus and on-campus. We have the turn of the curve with strong growth as of Q3, and we see continuing to 2027.1, restating that this is too early. We may have perhaps some better demand or in 2026.1 may be impacting 2027.1. We have several scenarios that require this analysis. It is early to draw conclusions. The initial indicators to us are quite positive, and we are seeing the market speaking on the same tones in the other calls that we have attended.
On 6x1 scale, what it impacts us is the compensated weekly rest for our faculty members that are paid by the hour. The way it is today, the decree would have a negative impact for the cost, especially in faculty costs for next year. We don't believe this will be established like that. It's far from what we call the spirit of the law. It comes to increase the numbers that are not worked overall. Those that actually work six days a week will start working five days. This should not impact professors that are paid by the hour. The text of the law actually drives some costs for those professors. During the regulation or the enactment of this law, this should be adjusted so we don't work with a negative impact part for 2027.1.
We have associations working with the relevant agencies so that this adjustment could be made. Our idea is not to have cost impact on 2027.1, but of course, we should be monitoring that. Thank you for your question.
Thank you.
Our next question is from Leandro Bastos from Citi.
Good morning. Thank you. Two questions. Intake, when we look at the Q3 numbers on- campus and semi, quite good on average, stronger than we've seen from other market players. I'd like to get your diagnosis. Why has this intake been above average? If you could share with us, what were the main levers? You've mentioned a few things, but we would like to have some more flavor on your diagnosis on Q3. First point. And the second, moving to cash generation, another highlight in the quarter.
I'd like to understand, there is this dividend commitment, BRL 750 million with the deal with Afya, so we have predictability, and we thinking about the period until closing, BRL 750 million is the goal for cash generation, 12 months ahead. And another quick point, if you've had any definitions on the announcements of those dividends as to how they should happen. Just these points. Thank you.
Thanks, Leandro. Thank you for your questions. They have been three. And I'm going to organize here. Intake of semi and on-campus, our diagnosis, I think several factors. Semi first. Semi, it's a continuity. We had good intake over the quarter Q3, reinforces this positive trend. We have two waves, and we have digital to semi, the Ministry of Education establishing as a modality. Actually, it was established by the private education system as of the new regulatory framework. You make it official.
It is determined what it is clear for the students, and so comparability, it actually makes it more attractive for students. Students seek a balance between flexibility that distance learning gives with the quality they see on the on-campus. So this semi on-campus is quite advantageous for a large share of students. So this is something we see in the market as a whole. We are more accelerated than the majority because we started later. You have two important market players that started that before us, strong operations in semi-on-campus. We were a bit late, and we have the benefit of being the follower, so we have things here. So we have catch-up to make. So our brand has its natural share in all our segments in semi-on-campus.
We were below our fair share, so there's a catch-up to happen in addition to very well-conducted strategy, Rodolfo and everybody's team of outreach of semi-on-campus in the Rodolfo structure of our partners. Before, they had a low offer in semi-on-campus. We have several hubs offering semi-on-campus. We're expanding gradually this outreach of semi-on-campus for the whole of Brazil. So we have increase in all hubs. This should keep on moving not only this year, as well next year. So we're very positive about this. Okay, on-campus. It was a trend that we saw that on the horizon. It was getting closer. We thought this would be happening before. It's a year impacted by elections. Election year is very difficult for intake in higher education, so it delayed a bit the recovery in on-campus.
A World Cup year, we clearly see in all our panels, the view pre-, during, and post-World Cup, clearly decreasing demand. Once those periods are over, you start capturing that positive horizon that we saw on-campus. It suffered a lot initially with FIES, and then during the pandemic, 2019, pre-pandemic, we saw a recovery of on-campus. It was strongly impacted by the pandemic. After pandemic, from 2023 to now, we expect it would stabilize between 2024/ 2025, and it should grow a single- digit, not very fast, but constant growth level. This 8% part, there was perhaps potential pent-up demand, and we should have the growth that we expected to have in this low- single, or a low- single. We prepared for that. We are the largest company in terms of on-campus offerings. We're present practically in all states of Brazil.
Campuses, the shape for this modality, the non-recurring, we made important investments to restructure the campuses for the appropriate size, the new type of demand, all personnel structure adapted. So we see sustained structure and very well-balanced cost structure that should have profitable growth, not only for on-campus, but for YDUQS as a whole.
To your second question on cash generation, it's in line with what we have been talking about. We've become a company that is a strong cash generator on 2025, so we are kind of skeptic seeing the reproduction of good performance from 1995 to, from, 2025 to 2026. It should keep on growing, and it should keep growing as the EBITDA grows. Cash conversion is much higher, and it should follow this moment. BRL 750 million, it's not actually a goal, but it's certainly a number that is reachable in this period.
For those to understand the context of the question, BRL 750 million in the agreement signed with Afya, that depends on the approval of our general meeting. On the 25th of November, there was an agreement that YDUQS would pay at least BRL 750 million of dividend for its shareholders or cash generation in the period that is higher.
Leandro's point is, correct me if I'm wrong, if we believe that over this period, by the closing, we would be able to generate the BRL 750 million in the period 12 months. This is quite likely. We cannot get it totally accurately, but it is possible to generate BRL 750 million or even more within a 12-month period. That should be coinciding with our estimate of the closing period. I think this is it. Have I left anything out?
No, it was just the timing of dividends.
Yeah, there was a third part. This decision will be made after general meeting. We're waiting to have the general meeting to be held. It's been happening within the board, and we're waiting for the general meeting definition, and we'll communicate that. Communicating dividends at year-end, and we should show the horizon of the BRL 750 million.
Thank you very much.
Thank you. Felipe Amancio from BBA.
Good morning. Two questions on my side. First on ENAMED, the medical school examination. You talked about medicine coming from restrictions of ENAMED. If you could elaborate on the measures to mitigate such effects, it would be nice and get an update of expectations for the future results of ENAMED. Second question is on personnel cost. We notice in various results in this sector cost due to the regulatory framework.
I'd like to understand how much this expected personnel cost is already shown in the results to get an update if you see some additional cost that should come up in this line of cost in the forthcoming quarters. Thank you.
Thank you. Good questions. I'm going to outsource both. Let's start with the second. I'm going to ask Aquino to address the second, and then I'll ask Silvio to talk about ENAMED. Thank you.
Felipe, good morning. I think it's a very good question. Personnel cost, if you look first half results over the whole year, we are impacted by the regulatory framework in the following way. There's been a large migration of students coming from digital to semi on-campus and from semi to on-campus. This migration increases the cost of faculty because we have more on-campus. This increased by 1 percentage point our cost.
And we have something additional 0.3 percentage points for cost increase due to the full implementation of the regulatory framework. We have that expected for next year. We have been sharing that with the market. We have an impact this year that is very much focused on the increase of transfers to the hub so that it can prepare their infrastructure from there on to have on-campus infrastructure to service students according to the framework. And next year, we should get to 0.7 percentage points of cost increase, and that would be mostly or essentially on personnel. Do you have any other questions, anything that is not clear?
Exactly that, just the point of ENAMED.
Okay, can you hear me all right?
Yes.
Thank you, Felipe, for your question.
Actually, ENAMED brought to us a very interesting possibility of moving forward with certain aspects related to individualizing students, understanding gap student by student. So establish a lot of academic measures, text ID by text ID, not only the groups, while looking at student by student by student, the several actions as mock examinations with similar questions of ENAMED, evolution. And we have an academic observatory where we can identify the coefficient of students' attainment. And with mock examination, we had several modalities and some reproducing number of questions of ENAMED, and actually smaller mock examinations so that they can better work on the questions. And the fact is that we've managed through these various indicators, observe and act upon the students that had higher or bigger gaps. We developed a work of mentorship that was more customized and followed their development at every mock examination.
What we observe in this more personalized work, specific look at the needs of student by student reflected in better results in the following mock examination. So, on the date of the examination, they have great improvement. And from the assessment that we had of the students, our outlook is very positive. We see great leaps. It is important to remember that ENAMED, you evaluate different seasons of course with a different group of students. So for a course, you may have a certain performance, and that group is naturally would have totally different performance because there are differences considering, well, we have more external transfers in the class. Sometimes students are in the course, have been in the course since the very first day.
So we have several academic measures, and the snapshot we have now gives us very positive outlook with the satisfactory positioning in all the students that took the examination.
Thank you very much.
Thank you. Next question is from Gustavo Tiseo from XP. Your microphone is open.
Thank you for your availability. I have to first will address the previous question. I would like to connect. So you have the cost of a new legal framework, ENAMED, and you talked about margin pressure from now on. Correct me if I am saying something wrong. It seems that you are speeding up costs above what the industry was expecting, not only for you, but for everyone, part coming from medicine as well.
When you think about the budget you had for 2027, was there any margin increase that was more significant coming from those investment, be it on the medical school or the new legal framework, considering what we have today on a competition, people trying to take FIES and transfer it to ticket to have higher cost? Is there something that is more impactful that could have a negative impact on margin 2027? And going back to the dividends or cash generation, BRL 750 million, your receivables have been reduced, and working capital has a positive moment due to this and the company's strategy. Is there anything that we can think as to where receivables could and how much you can improve there to help in a cash generation from now on? Thank you.
Thank you, Gustavo. Good questions.
I am going to address it first, and then I turn it over to Aquino to add, and then he will answer the second. We have heard the cause of the remaining of the market. Q3 specifically has some higher expenses. Well, let us break down the answer. What is specific? What is for next year? We talked about medicine Q3, the support to the performance of ENAMED. We felt it was important at this time. There was a change, to remind you, not radical, but relevant in the way the courses were analyzed, so we needed to fastly react. So it takes six years for you to have a doctor trained, so we had to prepare to a specific examination, which was not the focus of the course.
In a short term, we had to adapt your teaching model for upperclassmen so that they could be prepared for the examination.
We had an increase in spending to tackle the examination, which is important to us. It has consequences that may be negative for the course, super important for our performance. We decided correctly, in our view, to spend a bit more. That was just specific. It should not be recurring. The teaching model will adapt. We find our levels, and the margin will stabilize. This should not be higher spending in a recurring format. This should not impact 2027. We also have an increase that is partial spending. Medical schools are still maturing. Some courses do not have six complete classes. In this maturing process, we increase the cost structure of a company, so we should have this year, maybe next year, greater cost pressure due to this maturation period.
There is a slight cost increase that should be recurrent in the maturation, but we do not believe it is relevant.
I think Aquino mentioned that. We see this medicine margin closing. That will be a margin that will be maintained in the next years. In terms of semi-structure, Estácio & Wyden, considering the framework, we do not have a uniform move in the industry as a whole. Our forecast is exactly as you said, loss of margin 0.7 percentage points to the company. Next year, half of this negative impact has already been executed in 2026. We should have an impact of half of this 0.7%, and next year, the impact will complete for the final 0.7%. It is an increase in personnel. We need to have more people present for the on-campus increase, and also transfer to support the infrastructure of the hubs that should actually lead to this slight loss in margin. This is not something that impacts all areas. Some factors lead to different increases.
We had a regulation that was called fast track in nursing, for example, where we had the migration of nursing from a model that was the umbrella of distance learning to move to semi on- campus, and it had to be moved to on- campus. You need a campus for that. You cannot do it in a hub. We had a fast track approval measure. Some campuses should. Some hubs have to be transformed into campus, so we need to invest on those hubs to turn them into a campus. So increase your cost structure, not only initial investment, but you increase the cost structure. This path, it has an impact in your cost structure. You cannot have relevant revenue increase, appropriate ticket for on- campus. This may lead to a pressure on the margin. This has not been the way we have grown.
We have not been benefited by the fast track legislation. It is just for organizations that started way back when. We had a larger volume of students in 2024. This is not the model we are following. We did not have the pressure of structuring fixed costs due to this. Even with the benefit of fast track, you see we have quite strong growth in semi on-campus. This gives us greater structuring of our hubs, and the growth of on-campus comes from the structure that we already have that is very strong in all Brazilian states. We do not see a heavier cost for the delivery of on- campus that is required by the framework. So things continue just as we commented before. I am going to turn over to Aquino to talk about dividends.
Well, I think Rossano has been quite complete in his answer. I think there is something that is very relevant.
We had a loss in margin comparing year- over- year, most of it explained by the displacement of the sale of the portfolio. If we hadn't displaced the sale of the portfolio, we would have a very similar margin to last year, looking ahead, closing this question of cost and talking about dividends and cash generation. Last year, we generated BRL 500 million of cash flow for shareholders. Everybody looked at 2026 and said, Okay, we had a help, very positive impact of the working capital variation, this will not happen next year. This is not sustainable. Same thing happened from 2024 to 2025.
We always said that, Well, this actually seems to be like this because what we've been doing, making projections of non-engaged, this, several things we've been doing here, they impact negatively on our accounting number, but they do not have this impact that is negative in cash generation. First, this comes up as in cash generation as an improvement in the working capital, and then this is transformed into lower bad debt. You've seen that. It's been reducing, and it should have happened in Q3 if it hadn't been for the displacement of the portfolio sale. We'll keep seeing that ahead, the reduction in bad debt. So we'll replace somehow this positive variation of cash generation by better bad debt performance. We're very confident on sustainability of this level of cash generation that we have today.
Thank you.
Thank you. Our next question is from Mauricio Cepeda, Morgan Stanley.
Thank you. We actually have two questions. The adaptations that you have to make for the regulatory framework, you have to actually complete things by 2028. You've mapped out a small loss of margin. Considering that you're now merging with Afya and you have more pressure on C class, may not have the evolution that you had before. One of the expenses you had at Estácio & Wyden. Have you thought about simplifying portfolio precisely to avoid those adaptations and actually have a different profile for a new reality or not? Are you adapted to the point that the portfolio would not have to be readapted? This is the first question. The second is the part of Sorry, I mixed it up.
Of your cash that we were mentioning previously, as Aquino said, working capital helped a lot, and you would keep a certain level. Do you see any growth lever for cash? It would have a cash generation stability because the EBITDA would more stabilize, and working capital would not have this boost or drive that it's had in the past year as well.
Thank you, Mauricio Cepeda. On the framework, you mentioned a reduction in the portfolio. Well, we had to review geographic portfolio, not only us, but the industry as a whole. We are reducing the number of hubs, and we have small ones, and it's hard to have a hub structure that is more expensive. So for you to service smaller towns, we should have a volume of hubs. Everybody's going through this reduction of the number of hubs, and the impact in revenue is small.
The revenue was little concentrated. The impact should be small for the changes overall. This move to us is already reflected in the margin loss that we talked about. First, impact geographic happened, enforced by the framework as a whole, but not only us, but the whole industry. We prioritize other projects. We remove several projects from the offering in distance learning and move to on-campus. You reduce your offering of our cheaper products, and you increase the offerings in semi on-campus and on-campus. We see that as very positive, and semi and on-campus, we have stronger modes, and we can actually strengthen the large companies that have investment capability of more structured and qualified things. We see that in Q3. This should be stronger in Q4.
We should close the year with the migration that is going to be very positive from distance learning to semi on-campus. This should strengthen organizations that have capability and potential to expand that. Our expansion has been very successful. As we said, we do not have in our hubs the offerings that we would like to have on semi on-campus. Sometimes you have the hub offering, it is a good product, and different from what you provide in the original hub. So we are changing the offerings in cities and towns that are relevant. They are moves that are made by the market with positive results that we are working a lot to capture benefits that are being worked on at Estácio & Wyden and overall. Aquino will complete the answer.
Thank you, Mauricio, for your question. So we are closing our budget now. We are going to have a better idea of cash generation after those variations.
Now, we have positive and negative things when we look ahead. So we are much less leveraged. We have a much better leverage than last year. This helps us for cash generation next year. We have the end of a positive effect, so we have the change in receivables. Our private funds or financing helped us in about BRL 34 million. Last year, it was almost BRL 90 million. So we had an increase in the tail that was important for cash generation this year, and will generate cash positively, possibly next year. So, the solid operation reduction in the average interest rate reduction, and on the other hand, we have the end of this positive effect of working capital and the change due to the change in the financing model. So we have growth year-over-year after legal framework.
We had an improvement in cash generation, our expectation that we keep on growing next year as well. So overall, we should have a similar year, even better perhaps, but nothing points out that we are going to have a year that is going to be worse next year than this year.
Great. Thank you.
Our next question is from Thiago Marmo from Safra.
Good morning, everyone. I have two questions. One is on depreciation. Alexandre Aquino mentioned that there is still a difference between the level of depreciation and the current investment level that started dropping this year. I would like to understand the pace at which this difference may have, and if you can have convergence in investment starting in 2027. Second question would be on tax. You mentioned that the income of the quarter had lower recognition of the deferred, well, has changed this recognition of deferred expenses.
How you should look at the rate from now on? These are two of my questions, and thank you and congratulations on our results.
Thank you, Thiago. Aquino will answer your questions.
Well, thank you. Regarding depreciation, in the past, we made great investments in physical assets and bricks, and that was transformed into digital investments, and the depreciation was faster. The reduction that we made of investments takes some time to close and get the two items closer. Last year, 2025, so we had BRL 50 million difference. I think we will close around BRL 20 million. For next year, we should keep on growing. We do not have yet our budget for next year, but it would be reasonable for us to expect similar reduction that we had this year between the difference of CapEx and depreciation and amortization. But I do not have the accurate numbers to share.
The path is this one, to keep on reducing. It is worth mentioning, well, we have some points there, the difference of IFRS 16 and rent and net income regarding rent, and it drops on two lines of depreciation and financial results. We have BRL 30 million, and we have this difference of legal expense. What we disperse in legal actions is at a level of BRL 50 million below what we acknowledge. All of that gives this difference that last year was about BRL 130 million. In the past 12 months, we see a difference around BRL 110 million. It has been dropping and tends in the midterm to be equalized. We still have a quite different level. There is this difference of net income and cash generation.
When we talk about deferred tax, since we had smaller growth of expenses and spending, those differences actually impact deferred taxes because part of what I have as spending, I cannot acknowledge as in tax payment immediately. So everything I have a provision, I have a rule for tax recognition that is different from the accounting one. It makes us to have this deferred tax. When I have a slower growth, I can have a slower recognition of deferred. That was the reason why we had those results in deferred recognition or deferred taxes. When we account for total taxes, it is still positive. It is less positive than last year, but we have sudden cash disbursement. There is a difference between the tax that we acknowledge accountingly. So this number figure is 2%- 3% the effective disbursement for income taxes.
Number is perhaps more important than the tax we acknowledge accounting-wise.
Perfect. Thank you very much.
Thank you. The Q&A session is closed now. I turn over to Mr. Rossano Marques to make the company's final remarks.
Thank you very much for your participation to all of you. Another quarter that shows our great trust and confidence in our guidance 2026 and starting to think about 2027. All the principles of our business strategy remain intact and very strong. Happy with this turn of the curve on-campus and Estácio & Wyden, with strong positioning that we have of EBITDA margin, EBITDA margin cash generation, strong, keep proving our trust in the capability of the coming, being a strong cash generator and reducing leverage. Only positive messages. I once again thank you for your presence and greetings to all of you.
The YDUQS video conference is closed. We thank everyone for your participation and wish you a good day.